These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 18195530

  • 1. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
    Kobayashi N, Fujita K, Fujisawa T, Takahashi H, Yoneda M, Abe Y, Inamori M, Kirikoshi H, Kubota K, Saito S, Nakajima A.
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
    [Abstract] [Full Text] [Related]

  • 2. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M, Jiang X, Zhang M, Xu H, Zhai G, Li B.
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [Abstract] [Full Text] [Related]

  • 3. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M.
    J Clin Oncol; 2009 Jul 10; 27(20):3303-11. PubMed ID: 19451443
    [Abstract] [Full Text] [Related]

  • 4. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
    Sun Y, Duan Q, Wang S, Zeng Y, Wu R.
    J BUON; 2015 Jul 10; 20(2):452-9. PubMed ID: 26011335
    [Abstract] [Full Text] [Related]

  • 5. Single 20-second acquisition of deep-inspiration breath-hold PET/CT: clinical feasibility for lung cancer.
    Torizuka T, Tanizaki Y, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Ouchi Y.
    J Nucl Med; 2009 Oct 10; 50(10):1579-84. PubMed ID: 19759111
    [Abstract] [Full Text] [Related]

  • 6. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
    Karam M, Ata A, Irish K, Feustel PJ, Mottaghy FM, Stroobants SG, Verhoef GE, Chundru S, Douglas-Nikitin V, Oliver Wong CY, Brepoels LM.
    Nucl Med Commun; 2009 Oct 10; 30(10):770-8. PubMed ID: 19657307
    [Abstract] [Full Text] [Related]

  • 7. Response to preoperative short-course radiotherapy in locally advanced rectal cancer: value of f-fluorodeoxyglucose positron emission tomography.
    Siegel R, Dresel S, Koswig S, Gebauer B, Hunerbein M, Schneider W, Schlag PM.
    Onkologie; 2008 Apr 10; 31(4):166-72. PubMed ID: 18418017
    [Abstract] [Full Text] [Related]

  • 8. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
    Sato M, Okumura T, Kaito K, Kiyoshima M, Asato Y, Uchiumi K, Iijima H, Hashimoto I, Kaburagi T, Amemiya R.
    Ann Nucl Med; 2009 Jan 10; 23(1):49-57. PubMed ID: 19205838
    [Abstract] [Full Text] [Related]

  • 9. Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
    Goh BK, Chung YF, Ng DC, Selvarajan S, Soo KC.
    JOP; 2007 May 09; 8(3):350-4. PubMed ID: 17495366
    [Abstract] [Full Text] [Related]

  • 10. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
    Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A.
    J Clin Oncol; 2006 Oct 01; 24(28):4587-93. PubMed ID: 17008700
    [Abstract] [Full Text] [Related]

  • 11. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
    Bar-Shalom R, Kagna O, Israel O, Guralnik L.
    Cancer; 2008 Dec 01; 113(11):3213-21. PubMed ID: 18924145
    [Abstract] [Full Text] [Related]

  • 12. [The role of / 18FDG PET/CT for the initial staging and therapy in primary breast cancer].
    Inokuchi M, Furukawa H, Kayahara M, Ohta T, Kawashima H, Taki J, Kinuya S.
    Gan To Kagaku Ryoho; 2009 Dec 01; 36(13):2526-31. PubMed ID: 20009451
    [Abstract] [Full Text] [Related]

  • 13. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA.
    Eur J Radiol; 2012 Jan 01; 81(1):e19-25. PubMed ID: 21129871
    [Abstract] [Full Text] [Related]

  • 14. Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
    Kawada K, Murakami K, Sato T, Kojima Y, Ebi H, Mukai H, Tahara M, Shimokata K, Minami H.
    Jpn J Clin Oncol; 2007 Jan 01; 37(1):44-8. PubMed ID: 17060407
    [Abstract] [Full Text] [Related]

  • 15. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ, Thurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M, Geschwind JF, Salem R.
    J Vasc Interv Radiol; 2005 Dec 01; 16(12):1641-51. PubMed ID: 16371530
    [Abstract] [Full Text] [Related]

  • 16. F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers.
    Haug AR, Schmidt GP, Klingenstein A, Heinemann V, Stieber P, Priebe M, la Fougère C, Becker C, Hahn K, Tiling R.
    J Comput Assist Tomogr; 2007 Dec 01; 31(4):629-34. PubMed ID: 17882045
    [Abstract] [Full Text] [Related]

  • 17. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
    Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum O, Horton KM, Kamel I, Macura KJ, Tsai HL, Kowalski J, Wahl RL.
    J Nucl Med; 2009 Nov 01; 50(11):1760-9. PubMed ID: 19837757
    [Abstract] [Full Text] [Related]

  • 18. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer.
    Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, Hyun SH, Park K, Ahn MJ, Ahn YC, Kim HJ, Ko YH, Baek CH.
    Clin Cancer Res; 2009 Sep 15; 15(18):5861-8. PubMed ID: 19737951
    [Abstract] [Full Text] [Related]

  • 19. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy.
    Yoon DH, Baek S, Choi CM, Lee DH, Suh C, Ryu JS, Moon DH, Lee JS, Kim SW.
    Clin Cancer Res; 2011 Aug 01; 17(15):5093-100. PubMed ID: 21673067
    [Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.
    J Nucl Med; 2009 May 01; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.